Arcutis Biotherapeutics (ARQT) Stock Statistics & Valuation Metrics

Arcutis Biotherapeutics has a market cap or net worth of $1.83B. The enterprise value is $1.88B.

Arcutis Biotherapeutics has 119,201,720 shares outstanding. The number of shares has decreased by -2.65% in one year.

Arcutis Biotherapeutics’s return on equity (ROE) is -0.89 and return on invested capital (ROIC) is -48.01%.

The current PE Ratio of Arcutis Biotherapeutics is ―. Arcutis Biotherapeutics’s PEG ratio is ―.

In the last 12 months, Arcutis Biotherapeutics had revenue of 196.54M and earned -140.04M in profits. Earnings per share was -1.16.

In the last 12 months, operating cash flow was -110.94M and capital expenditures -5.75M, giving a free cash flow of -116.69M billion.

Arcutis Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Arcutis Biotherapeutics upcoming earnings date is Nov 5, 2025, After Close (Confirmed).

Arcutis Biotherapeutics as a current ratio of 4.15, with Debt / Equity ratio of 77.67%

In the past 12 months, Arcutis Biotherapeutics has paid 647.00K in taxes.

Arcutis Biotherapeutics EV to EBITDA ratio is -15.73, with an EV/FCF ratio of -15.35.

Arcutis Biotherapeutics has $198.09M in cash and marketable securities with $110.80M in debt, giving a net cash position of -$87.29M billion.

Gross margin is 88.39%, with operating margin of -65.33%, and net profit margin of -71.25%.

The average price target for Arcutis Biotherapeutics is $21.41, which is 11.43% higher than the current price. The consensus rating is Strong Buy